Wockhardt Ltd

Wockhardt Ltd

Next 500 2024
+ 13 More
+ 13 More
OVERVIEW
FINANCIALS
NEWS

About

Wockhardt Limited is a global pharmaceutical and biotechnology company. The company was established in 1967 by Dr. Habil Khorakiwala, who also serves as the Chairman. Wockhardt is headquartered in Mumbai. The company’s products include branded and generic formulations, APIs, contract manufacturing and new drug development. Wockhardt is known for its inventions such as India's first automatic insulin delivery device (Wosulin Pen) and the introduction of Povidone Iodine (Betadine) with Mundi Pharma. Wockhardt's manufacturing facility is present in Chikalthana, Chhatrapati Sambhajinagar. The company operates through six super speciality tertiary care hospitals. Wockhardt’s credo "LIFE WINS” underscores their commitment to healthcare. The company’s global team is a multi-ethnic workforce of 8,600 Wockhardt associates from 21 different nationalities

Incorporation Year: 1999
Headquarters: Mumbai
Top Management: Founder Chairman- Dr. Habil Khorakiwala
Industry: Pharma

Featured In Fortune India Ranking

Fortune 500 India
#456(2022)
#313(2021)
#376(2020)
#308(2019)
#310(2018)
#278(2017)
#254(2016)
#238(2015)
#229(2014)
#156(2013)
#202(2012)
#213(2011)
#188(2010)
#456(2022)#313(2021)#376(2020)#308(2019)#310(2018)#278(2017)#254(2016)#238(2015)#229(2014)#156(2013)#202(2012)#213(2011)#188(2010)
Ranking Trend Fortune 500 India
Next 500 India
#116(2024)
#116(2024)

Financial Data 2024

Revenue
2,895
(INR Cr)
Net Operating Income
2,798
(INR Cr)
Assets
6,118
(INR Cr)
Profit
-463
(INR Cr)
Net Worth
3,359
(INR Cr)

Fortune India Coverage

Financial Data

RevenueNet Operating IncomeProfitAssetsNet Worth
PARAMETERS2024202320222021202020192018201720162015201420132012201120102008
Revenue
(INR Cr)
2895
7.7%
2689
-15.0%
3163
-19.9%
3950
36.1%
2903
-20.5%
3652
-5.9%
3879
-6.7%
4155
-9.4%
4584
-0.3%
4599
-7.4%
4966
-15.9%
5902
30.3%
4530
17.9%
3842
-17.7%
4666
27.3%
3666
-
Net Operating Income
(INR Cr)
2798
5.55%
2651
-17.93%
3230
19.28%
2708
-4.78%
2844
-20.24%
3566
-9.43%
3937
-1.94%
4015
-9.85%
4453
-0.63%
4482
-7.22%
4830
-13.89%
5609
28.94%
4351
15.97%
3751
-16.67%
4501
25.40%
3590
35.25%
Profit
(INR Cr)
-463
-
-559
-
-244
-
686
-
-69
-
-195
-
-608
-
-196
-
251
-38.1%
405
-51.8%
841
-47.3%
1594
365.2%
343
278.6%
91
-
-1001
-
-139
-
Assets
(INR Cr)
6118
2.8%
5950
-9.6%
6584
1.0%
6517
-2.5%
6685
3.9%
6433
-8.2%
7011
-12.1%
7973
14.1%
6988
17.7%
5939
4.6%
5676
17.2%
4845
0.2%
4837
10.4%
4381
-6.6%
4689
-10.7%
5253
-
Net Worth
(INR Cr)
3359
0.2%
3354
-12.9%
3849
14.0%
3376
26.4%
2672
-0.1%
2675
-6.2%
2852
-14.5%
3337
-11.6%
3775
10.5%
3417
4.1%
3283
36.5%
2406
239.0%
710
258.6%
198
-
3
-99.7%
1018
-20.1%
Employee Cost
(INR Cr)
629
-1.3%
637
-15.0%
749
-1.8%
763
2.7%
743
-7.1%
800
-14.6%
937
-3.1%
967
1.7%
951
9.4%
869
13.0%
769
17.2%
656
14.5%
573
5.6%
542
-26.2%
735
16.3%
632
-
Interest Cost
(INR Cr)
3053022992492762652552251295583215269267342259
Cash & Bank Balance
(INR Cr)
529124406292268449108216041478123511261096700483347650
Total Debt
(INR Cr)
2356218421982674358231413748416026772010190620703281339040184235

Key Financial Ratios

Profit As % Of RevenuesRONW %Interest Cost to EBITDA %ROCE %Debt to Equity Ratio
PARAMETERS2024202320222021202020192018201720162015201420132012201120102008
Profit As % Of Revenues ---17.4%----5.5%8.8%16.9%27.0%7.6%2.4%--
Profit As % Of Assets ---10.5%----3.6%6.8%14.8%32.9%7.1%2.1%--
Profit As % Of Networth ---20.3%----6.6%11.9%25.6%66.3%48.3%45.7%--
Interest Cost to EBITDA % 1220.0%-260.0%-231.7%--1759.9%26.1%7.8%9.2%10.4%30.5%79.6%-371.0%
Debt to Equity Ratio 0.700.650.570.791.341.171.311.250.710.590.580.864.6217.13-4.16
RONW ---27.5%----7.0%12.3%29.6%102.4%128.0%---
ROCE -0.9%-0.5%1.2%13.0%0.5%-1.4%-1.3%-0.9%6.8%11.1%18.8%42.7%28.6%21.0%0.0%12.5%